surpass cvot tirzepatide 💡 New insight in diabetes care: In patients with T2DM and ASCVD, the SURPASS-CVOT trial found that was noninferior to dulaglutide for major cardiovascular events (12.2% vs 13.1%; HR 0.92). What Inside SURPASS-CVOT With Dr. Stephen

1.39k views 45 slides Aim: Learn about causes and effects of ozone depletion Aim: Learn about causes and effects of ozone depletion New words: ozone, ozone layer, troposphere, stratosphere, U.V

This effect is believed to stem from semaglutides impact on inflammatory pathways, though more research is needed to fully understand how it may influence RA symptoms

In patients with a body mass index corresponding to being overweight, plasma glucose reduction has been reported

Evidence of superiority over standard glutathione is lacking [17]

Weeks 17-24: Sustained Progress Weight Loss: 17-20% cumulative (42-50 pounds total) Dose: 9mg or 12mg maintenance Primary Focus: Consistency and optimization Weight loss continues at 2-3 pounds per week